Author details

Full Name

Meenakshi Anurag

Affiliation

ORCID

Career Start Year

2009

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37501682	Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment.	Cancer Res Commun	2023
37587913	Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins.	Cancer Res Commun	2023
37137501	The Breast Cancer Proteome and Precision Oncology.	Cold Spring Harb Perspect Med	2023
37071495	Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.	Cancer Res	2023
37066845	How valuable can proteogenomics be in clinical breast cancer research?		2023
36258226	Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness.	Breast Cancer Res	2022
35653124	Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031).	Clin Cancer Res	2022
36001024	Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.	Cancer Discov	2022
36273232	Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancer.	Sci Rep	2022
35736563	Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer.	Cancer Research	2022
34711608	Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.	Cancer Res	2021
34173924	ImmunogenomicÂ profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.	Breast Cancer Res Treat	2021
33417831	Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma.	Cancer Cell	2021
34504086	Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer.	NPJ Breast Cancer	2021
31522348	Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.	Breast Cancer Res Treat	2020
32142667	Neurofibromin Is an Estrogen Receptor-Î± Transcriptional Co-repressor in Breast Cancer.	Cancer Cell	2020
32191303	Response to JÃ©zÃ©quel, Patsouris, Guette, et al.	Journal of the National Cancer Institute	2020
31690650	CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree?	Clinical Cancer Research	2020
31631213	Universal concept signature analysis: genome-wide quantification of new biological and pathological functions of genes and pathways.	Briefings in Bioinformatics	2020
31665365	Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).	J Natl Cancer Inst	2020
32564259	Correction to: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.	Breast Cancer Res Treat	2020
31099189	Copy number alterations associated with clinical features in an underrepresented population with breast cancer.	Molecular genetics & genomic medicine	2019
31839155	Endocrine therapy resistance: new insights.	Breast	2019
29793947	Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers.	Clinical Cancer Research	2018
30555626	DNA damage repair defects as a new class of endocrine treatment resistance driver.	Oncotarget	2018
30429476	Author Correction: The prognostic effects of somatic mutations in ER-positive breast cancer.	Nat Commun	2018
30089255	Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.	Cell Rep	2018
30181556	The prognostic effects of somatic mutations in ER-positive breast cancer.	Nat Commun	2018
28801307	Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.	Cancer Discov	2017
27489360	Amplification of TLK2 Induces Genomic Instability via Impairing the G2-M Checkpoint.	Molecular Cancer Research	2016
22027861	Location of disorder in coiled coil proteins is influenced by its biological role and subcellular localization: a GO-based study on human proteome.	Molecular BioSystems	2012
22808064	Crowd sourcing a new paradigm for interactome driven drug target identification in Mycobacterium tuberculosis.	PLoS One	2012
21733180	A web server for predicting inhibitors against bacterial target GlmU protein.	BMC Pharmacology	2011
19763328	Unraveling the potential of intrinsically disordered proteins as drug targets: application to Mycobacterium tuberculosis.	Molecular BioSystems	2009